最新研究顯示：即使處于臨床緩解期，克羅恩病患者在工作上受到的影響程度仍高于普通人群

該行動旨在通過推行共決策的理念，助力患者在實現(xiàn)內(nèi)鏡緩解的同時，兼顧疾病管理與人生追求

新加坡2025年9月30日 /美通社/ -- 強生公司今日宣布在亞太區(qū)正式啟動"雙重人生"行動，旨在提升公眾對強化共決策（SDM）重要性的認知，更以這一理念為支撐，助力炎癥性腸?。↖BD）患者實現(xiàn)持續(xù)內(nèi)鏡緩解，讓患者在疾病管理與人生的雙向維度上握穩(wěn)"掌控權(quán)"，綻放更有質(zhì)量的生命狀態(tài)。這行動在亞太地區(qū)提供了一系列疾病教育資源。

作為IBD的兩種主要類型，克羅恩病（CD）和潰瘍性結(jié)腸炎（UC）影響著全球約1000萬人，且在亞洲的發(fā)病率呈增長趨勢^1,2,3。IBD多發(fā)于青少年時期⁴，常見癥狀包括腹瀉、便血、腹痛等癥狀⁵，不僅嚴重影響患者的學(xué)業(yè)⁶、職業(yè)發(fā)展⁷和人際關(guān)系⁸，更迫使患者過著表面正常，內(nèi)心煎熬的"雙重生活"。

在全球范圍內(nèi)，大約僅有10%的CD患者能夠達到臨床持續(xù)緩解⁹，多數(shù)UC患者仍主要依賴傳統(tǒng)治療方案¹⁰。近期，一項來自亞洲最大規(guī)模新診斷CD患者隊列研究iCREST-CD的子分析結(jié)果顯示，在臨床緩解的CD患者中，工作時受到影響的患者比例為25.7%，顯著高于日本整體人群的20.1%^11,12。這表明需要更有效的疾病管理以實現(xiàn)持續(xù)深度緩解。

近年來，中國UC患病率正快速攀升，預(yù)計2025年將超150萬例¹³。許多患者仍面臨診斷延遲、生物制劑可及性有限、疾病認知不足等挑戰(zhàn)。但通過早診早治、擴大治療選擇、加強疾病教育支持等措施，有望幫助更多患者在實現(xiàn)臨床緩解（以癥狀控制為主）的基礎(chǔ)上，進一步達到內(nèi)鏡緩解（即結(jié)腸鏡下無活動性病變）^14,15。然而，據(jù)相關(guān)調(diào)查顯示，僅不到40%的患者聽說過"黏膜愈合" (內(nèi)鏡緩解) 這一概念^15,16。

愛在延長炎癥性腸病基金會聯(lián)合創(chuàng)始人、浙江大學(xué)醫(yī)學(xué)院附屬第二醫(yī)院消化內(nèi)科陳焰主任醫(yī)師強調(diào)："醫(yī)生與患者之間對治療目標的認知差異凸顯了共決策的必要性。構(gòu)建互信的醫(yī)患關(guān)系和高效的溝通，不僅是彌合認知差距的關(guān)鍵路徑，更能有效推動患者深度參與到治療決策中，為其追求人生理想提供堅實支撐。"

不僅如此，醫(yī)患對"緩解"定義的認知差異也會影響治療預(yù)期和結(jié)果¹⁶?；颊咄J為"緩解"就是癥狀消失了，而醫(yī)生則會依據(jù)結(jié)腸鏡等檢測結(jié)果來界定這一概念¹⁵。值得注意的是，能通過內(nèi)鏡觀察到的緩解狀態(tài)，不僅與患者更高的生活質(zhì)量相關(guān)，還能降低其手術(shù)與住院風(fēng)險¹⁷，并提高持續(xù)緩解的可能性¹⁸。

研究顯示，共決策能夠促進醫(yī)患高效協(xié)作，從而改善治療效果¹⁹，但該理念在亞洲地區(qū)的應(yīng)用仍相對有限。據(jù)全球數(shù)據(jù)顯示，超過80%的IBD患者和醫(yī)生認同并支持共決策這一理念¹⁹。然而在日本，53%的患者擔(dān)心自己在就診時提問過多²⁰。在中國，30%患者對就診溝通的深度和時長感到不滿²¹。

為改善這一現(xiàn)狀，陳焰醫(yī)師及其團隊正依托數(shù)字化平臺，著力提升中國患者的疾病認知水平與治療參與度："長期以來，我們通過數(shù)字化工具和社交媒體加強患者教育，讓他們以更省時、省力、低成本的方式獲取關(guān)鍵信息，增強治療信心。"

在IBD領(lǐng)域深耕創(chuàng)新三十余載的堅實基礎(chǔ)上，強生正式啟動"雙重人生"行動，旨在攜手IBD患者社群，共促疾病診療模式的深度變革。強生創(chuàng)新醫(yī)療亞太區(qū)商業(yè)戰(zhàn)略副總裁Earl Dancel表示："我們致力于彌合診療與醫(yī)患溝通上的差距，幫助患者在有效管理疾病的同時，重新找回生活的主動權(quán)、追尋人生夢想。當患者掌握正確信息并積極參與治療時，內(nèi)鏡緩解就不僅僅是一種可能——它更成為實現(xiàn)雙重人生的重要途經(jīng)，讓健康與理想生活雙向同行。"

該公益行動已在亞太地區(qū)推出了系列活動，其中包括#我的雙重人生 醫(yī)患共決策賦能視頻，助力患者提升疾病管理主動權(quán); 即將在中國上線的#YouSeeUC科普項目，旨在打破患者對緩解認知的誤區(qū)并推行共決策理念；在日本推出的由醫(yī)療專家參與訪談的疾病教育內(nèi)容，為IBD患者提供平衡工作與健康的專業(yè)指導(dǎo)；在新加坡通過媒體分享患者真實故事，傳遞疾病管理經(jīng)驗。

關(guān)于"雙重人生"行動

"雙重人生"行動是一項新型患者賦能倡議，旨在通過提供科學(xué)的共決策（SDM）工具，彌合醫(yī)患在IBD治療目標認知上的差距。該行動與胃腸病學(xué)家、倡導(dǎo)團體及媒體合作，致力于通過共決策實現(xiàn)內(nèi)鏡緩解，助力患者同時掌控疾病管理與人生追求。

關(guān)于炎癥性腸病

炎癥性腸?。↖BD）是一類慢性非特異性消化道炎癥性疾病，主要包括克羅恩病和潰瘍性結(jié)腸炎¹。常見癥狀包括腹瀉、便血、體重減輕、口腔潰瘍及腹痛⁵。自21世紀以來，西方國家IBD發(fā)病率趨于穩(wěn)定，而亞洲地區(qū)發(fā)病率持續(xù)攀升³。IBD多發(fā)于青少年時期⁴，對患者的學(xué)業(yè)⁶、職業(yè)發(fā)展⁷及人際關(guān)系⁸均構(gòu)成影響。

目前IBD尚無法根治，主要治療目標是實現(xiàn)并維持緩解。IBD緩解包含以下層面：癥狀控制表現(xiàn)為活動性癥狀消失；內(nèi)鏡緩解指結(jié)腸鏡下未見活動性病變；組織學(xué)緩解則要求組織層面無活動性炎癥¹⁵。

關(guān)于強生

在強生，我們堅信健康就是一切。憑借在醫(yī)療健康領(lǐng)域的創(chuàng)新實力，我們致力于打造一個全新的世界。在這里，復(fù)雜疾病能夠得到預(yù)防、診療和治愈，治療方法更智能、更微創(chuàng)、更個性化?；谖覀冊卺t(yī)療科技和創(chuàng)新制藥兩方面得天獨厚的綜合實力，我們在整個醫(yī)療健康行業(yè)不斷創(chuàng)新突破，勇毅前行，為人類健康事業(yè)的發(fā)展帶來意義深遠的影響。

更多信息請訪問https://www.jnj.com/。

參考文獻

1. Crohn's & Colitis Foundation. (n.d.). What is IBD? Crohn's & Colitis Foundation. Retrieved September 4, 2025, from https://www.crohnscolitisfoundation.org/patientsandcaregivers/what-is-ibd
2. Pathiyil, M. M., Jena, A., Venkataramana Raju, A. K., Omprakash, T. A., Sharma, V., & Sebastian, S. (2023a). Representation and reporting of diverse groups in randomised controlled trials of pharmacological agents in inflammatory bowel disease: A systematic review. The Lancet Gastroenterology & Hepatology, 8(12), 1143–1151. https://doi.org/10.1016/s2468-1253(23)00193-0
3. Chen, X., Xiang, X., Xia, W., Li, X., Wang, S., Ye, S., Tian, L., Zhao, L., Ai, F., Shen, Z., Nie, K., Deng, M., & Wang, X. (2023). Evolving Trends and Burden of Inflammatory Bowel Disease in Asia, 1990-2019: A Comprehensive Analysis Based on the Global Burden of Disease Study. Journal of epidemiology and global health, 13(4), 725–739. https://doi.org/10.1007/s44197-023-00145-w
4. Rosen, M. J., Dhawan, A., & Saeed, S. A. (2015). Inflammatory Bowel Disease in Children and Adolescents. JAMA pediatrics, 169(11), 1053–1060. https://doi.org/10.1001/jamapediatrics.2015.1982
5. SingHealth. (n.d.). Inflammatory bowel disease – Conditions & treatments. SingHealth. Retrieved September 4, 2025, from https://www.singhealth.com.sg/symptoms-treatments/inflammatory-bowel-disease
6. Giga, A., Pappa, D., Manthou, P., Chryssi, M., Kollia, T., Varvitsioti, D., Giatromanolakis, E., Anastasiou, N., Zigkiri, E., & Mangoulia, P. (2024). Psychological Impact of Inflammatory Bowel Disease on University Students: A Systematic Review. Cureus, 16(4), e59176. https://doi.org/10.7759/cureus.59176
7. Marri, S. R., & Buchman, A. L. (2005). The education and employment status of patients with inflammatory bowel diseases. Inflammatory bowel diseases, 11(2), 171–177. https://doi.org/10.1097/00054725-200502000-00011
8. Rouncefield-Swales, A., Carter, B., Bray, L., Blake, L., Allen, S., Probert, C., Crook, K., & Qualter, P. (2020). Sustaining, Forming, and Letting Go of Friendships for Young People with Inflammatory Bowel Disease (IBD): A Qualitative Interview-Based Study. International journal of chronic diseases, 2020, 7254972. https://doi.org/10.1155/2020/7254972
9. Vermeire, S., Schreiber, S., Petryka, R., Kuehbacher, T., Hebuterne, X., Roblin, X., Klopocka, M., Goldis, A., Wisniewska-Jarosinska, M., Baranovsky, A., Sike, R., Stoyanova, K., Tasset, C., Van der Aa, A., & Harrison, P. (2017). Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial. Lancet (London, England), 389(10066), 266–275. https://doi.org/10.1016/S0140-6736(16)32537-5
10. Crohn's & Colitis Foundation. (2022, December 20). Study finds significant room for improvement in ulcerative colitis treatments. Crohn's & Colitis Foundation. Retrieved September 4, 2025, from https://www.crohnscolitisfoundation.org/blog/study-finds-significant-room-improvement-ulcerative-colitis-treatments
11. Tamura, A., Fujii, T., Chinen, M., Yoshigoe, S., Tsuchiya, H., Matsuoka, K., Okamoto, R., & Hisamatsu, T. (2025, July). Impact on work productivity and its association with fatigue in newly diagnosed patients with Crohn's disease: A sub-analysis of iCREST-CD [Conference presentation]. 13th Annual Meeting of the Asian Organization for Crohn's & Colitis (AOCC), Shinjuku-Ku, Tokyo, Japan
12. Matsuoka, K., Fujii, T., Okamoto, R., et al. (2022). Characteristics of adult patients newly diagnosed with Crohn's disease: Interim analysis of the nation-wide inception cohort registry study of patients with Crohn's disease in Japan (iCREST-CD). Journal of Gastroenterology, 57(8), 867–878. https://doi.org/10.1007/s00535-022-01907-2
13. Yu, Z., Ruan, G., Bai, X., Sun, Y., Yang, H., & Qian, J. (2024). Growing burden of inflammatory bowel disease in China: Findings from the Global Burden of Disease Study 2021 and predictions to 2035. Chinese medical journal, 137(23), 2851–2859. https://doi.org/10.1097/CM9.0000000000003345
14. Wan, J., Shen, J., Zhong, J., Ge, W., Miao, Y., Zhang, X., Wen, Z., Wang, Y., Liang, J., & Wu, K. (2024). Natural course of ulcerative colitis in China: Differences from the West?. United European gastroenterology journal, 12(9), 1167–1178. https://doi.org/10.1002/ueg2.12634
15. Wood, D. W., Treiman, K., Rivell, A., van Deen, W. K., Heyison, H., Mattar, M. C., Power, S., Strauss, A., Syal, G., Zullow, S., & Ehrlich, O. G. (2025). Communicating Information Regarding IBD Remission to Patients: Evidence From a Survey of Adult Patients in the United States. Inflammatory bowel diseases, 31(6), 1605–1615. https://doi.org/10.1093/ibd/izae201
16. Rubin, D. T., Sninsky, C., Siegmund, B., Sans, M., Hart, A., Bressler, B., Bouhnik, Y., Armuzzi, A., & Afzali, A. (2021). International Perspectives on Management of Inflammatory Bowel Disease: Opinion Differences and Similarities Between Patients and Physicians From the IBD GAPPS Survey. Inflammatory bowel diseases, 27(12), 1942–1953. https://doi.org/10.1093/ibd/izab006
17. Neff-Baro, S., et al. (2024, October 12–15). Endoscopic response at 1-year and association with long-term Crohn's disease outcome: A pooled clinical trial analysis adjusting for 1-year clinical remission status [Poster presentation, MP153]. United European Gastroenterology Week (UEGW), Vienna, Austria.
18. Kanazawa, M., Takahashi, F., Tominaga, K., Abe, K., Izawa, N., Fukushi, K., Nagashima, K., Kanamori, A., Takenaka, K., Sugaya, T., Iijima, M., Takada, A., Imai, Y., Hiraishi, H., & Irisawa, A. (2019). Relationship between endoscopic mucosal healing and histologic inflammation during remission maintenance phase in ulcerative colitis: a retrospective study. Endoscopy international open, 7(4), E568–E575. https://doi.org/10.1055/a-0869-7619
19. Crohn's & Colitis Foundation. (n.d.). Treatment approaches: Shared decision-making. Crohn's & Colitis Foundation. Retrieved September 4, 2025, from https://www.crohnscolitisfoundation.org/patientsandcaregivers/shared-decision-making
20. Watanabe, K., Gardiner, S., & Arai, S. (2022). Notable gaps between patients' and physicians' perspectives on communication and disease management in Japan: Multifaceted ad hoc analyses of the global Ulcerative Colitis Narrative Survey for further optimal care. Therapeutic Advances in Gastroenterology, 15, 1–12. https://doi.org/10.1177/17562848221095372
21. Xu, D., Zhang, H., & Chen, Y. (2021). Patients' views of shared decision making in inflammatory bowel disease: a survey in China. BMC medical informatics and decision making, 21(1), 340. https://doi.org/10.1186/s12911-021-01702-8